Clínica 69 based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992;71:599-604. 14 Van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents. Hum Reprod. 1999;14:2223-9. 15 Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome.Trends Endocrinol Metab. 2002;13:251-7. 16 Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361:1810-2. 17 Dagogo-Jack S, Al-Ali N, Qurttom M. Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab. 1997;82:2821-5. 18 Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90:2545-9. 19 Goldzieher JW. Polycystic ovarian disease. Fertil Steril 1981;35:371-94. 20 Balen AH, Michelmore K. What is polycystic ovary syndrome? Are national views important? Hum Reprod. 2002; 17:2219-27. 21 Birch RA, Padmanabhan V, Foster DL, Unsworth WP, Robison JE. Prenatal programming of reproductive neuroendocrine function: fetal androgen exposure produces progressive disruption of reproductive cycles in sheep. Endocrinology. 2003;144:1426-34. 22 Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome: a hypothesis. J Endocrinol. 2002;174:1-5. 23 Baumann EE, Rosenfield RL. Polycystic ovary syndrome in adolescence. The Endocrinologist 2002;12:333-48. 24 Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril. 2000;73:150-6. 25 Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J. Increased risk of non-insulin dependent diabetes mellitus arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod. 2000;15: 785-9. 26 Nestler JE. Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement. Hum Reprod. 2002;17:1950-3. 27 Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy II PF, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2562-8. 28 Elting MW, Korsen TJM, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod. 2001;16: 556-60. 29 Glueck CJ, Wang P, Goldenberg N, Sieve- Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17:2858-64. 30 Jakubowicz D, Iuorno M, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:524-9. 31 Li TC, Makris M, Tomsu M, Tuckerman E, Laird E. Recurrent miscarriage: aetiology, management and prognosis. Hum Reprod. Update. 2002;8:463-81. 32 Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet Med. 2004b;21:103-13. 33 Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovar-
70 Síndrome <strong>del</strong> <strong>Ovario</strong> Poliquístico ian syndrome. Hum Reprod. 2001;16: 226-9. 34 Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest. 2003;26:341-6. 35 Barbieri RL, Ryan K. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol. 1983;147:90-101.
Change language